NP / PA
Family Urgent Care, LLC.
Family Urgent Care, LLC. was paid $7.88M by Medicaid between Jan 2018 and Nov 2024, across 72 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 29% of everything it billed.
33Billing provider infoFAMILY URGENT CARE, LLC.
CHILLICOTHE, OH 45601
CHILLICOTHE, OH 45601
33aNPI1598107526assigned 07/18/2013
33bProvider typeFamily Health Clinical Nurse Specialist
28Total paid$7.88M
24GClaims318,403
24DCodes billed72
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,343 | $1.04M | |
| 2019 | 34,259 | $1.05M | |
| 2020 | 46,446 | $764K | |
| 2021 | 96,956 | $1.24M | |
| 2022 | 60,295 | $1.41M | |
| 2023 | 24,117 | $823K | |
| 2024incomplete | 31,987 | $1.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 29% | 38,748 | 35,845 | $2.25M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 29,358 | 25,814 | $1.37M |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 12% | 18,016 | 13,478 | $945K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 8.9% | 9,373 | 8,746 | $699K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 8.4% | 9,683 | 9,186 | $666K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 5.1% | 11,819 | 10,914 | $403K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 4.6% | 7,154 | 6,690 | $366K |
| 99205 | Prolong outpt/office vis | 4.0% | 4,283 | 4,130 | $318K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.1% | 10,417 | 9,642 | $168K |
| 86328 | 2.0% | 5,313 | 4,806 | $161K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.5% | 11,526 | 10,868 | $117K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.5% | 11,398 | 8,034 | $116K |
60 more codes
| 99051 | <1% | 5,740 | $68K | |
| A4927 | Gloves, non-sterile, per 100 | <1% | 10,419 | $55K |
| 87400 | <1% | 6,134 | $40K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,537 | $39K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 685 | $19K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 527 | $15K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 176 | $13K |
| 99201 | <1% | 529 | $8K | |
| 87807 | <1% | 578 | $7K | |
| 81025 | <1% | 1,061 | $5K | |
| 81000 | <1% | 683 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 315 | $3K |
| 86769 | <1% | 129 | $3K | |
| A4930 | Gloves, sterile, per pair | <1% | 12,317 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 85 | $3K |
| 81002 | <1% | 1,314 | $3K | |
| A4250 | Urine test or reagent strips or tablets (100 tablets or strips) | <1% | 3,038 | $3K |
| 86308 | <1% | 856 | $2K | |
| S9083 | Global fee urgent care centers | <1% | 12,580 | $2K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 61 | $2K |
| P9615 | Catheterization for collection of specimen(s) (multiple patients) | <1% | 354 | $2K |
| 81005 | <1% | 1,135 | $1K | |
| 3210F | <1% | 120 | $1K | |
| A4620 | Variable concentration mask | <1% | 2,197 | $906.18 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 847 | $892.43 |
| 87634 | <1% | 25 | $857.95 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 65 | $843.00 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 49 | $782.62 |
| 86664 | <1% | 80 | $773.44 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 533 | $661.10 |
| 86403 | <1% | 95 | $589.58 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 162 | $468.84 |
| 94761 | <1% | 127 | $415.79 | |
| 87535 | <1% | 84 | $387.74 | |
| 94664 | <1% | 46 | $384.58 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 105 | $291.20 |
| A4232 | Syringe with needle for external insulin pump, sterile, 3 cc | <1% | 95 | $224.71 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 12 | $174.15 |
| 81099 | <1% | 56 | $154.31 | |
| A4928 | Surgical mask, per 20 | <1% | 15,174 | $151.09 |
| 99072 | <1% | 4,844 | $148.56 | |
| 99070 | <1% | 20,892 | $147.50 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 20 | $101.50 |
| A4208 | Syringe with needle, sterile 3 cc, each | <1% | 569 | $94.31 |
| 86663 | <1% | 12 | $78.99 | |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | <1% | 5,408 | $58.80 |
| A4215 | Needle, sterile, any size, each | <1% | 1,268 | $31.14 |
| A4320 | Irrigation tray with bulb or piston syringe, any purpose | <1% | 176 | $22.50 |
| 94760 | <1% | 21,349 | $22.03 | |
| 99000 | <1% | 14,246 | $21.55 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 12 | $0.52 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 104 | $0.33 |
| A4258 | Spring-powered device for lancet, each | 0% | 122 | $0.00 |
| 99058 | 0% | 13 | $0.00 | |
| Q3014 | Telehealth originating site facility fee | 0% | 56 | $0.00 |
| 94762 | 0% | 24 | $0.00 | |
| 99071 | 0% | 21 | $0.00 | |
| A4606 | Oxygen probe for use with oximeter device, replacement | 0% | 25 | $0.00 |
| 99001 | 0% | 13 | $0.00 | |
| A4206 | Syringe with needle, sterile, 1 cc or less, each | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNAQVI, SYED (CEO)
| Provider | Location | Paid |
|---|---|---|
| Personic Virtual Clinic LLC | Columbia, MD | $777K |
| Inpatient Progressive Health of America, PLLC | San Antonio, TX | $715K |
| Imed Urgent Care LLC | Grove City, OH | $590K |
| SWH Naqvi MD PC | Long Beach, NY | $276K |
| High Point Healthcare LLC | Roswell, GA | $31K |
| Naqvi and Naqvi MD INC | Newport Beach, CA | $6K |
| Pulmonary Group of Newport Beach INC. | Newport Beach, CA | $3K |
| Ameripak Medical Associates PLLC | Mckinney, TX | $1K |
| Naqvi Health PLLC | Houston, TX | $130.46 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.